mn-166
Generic: ibudilast·Code: MN-166
mn-166: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| MEDICINOVA INC (MNOV) | Phase 2/Phase 3 |
Clinical Trials (1)
Phase 1b/2a Single-center, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of MN-166 (Ibudilast) and Temozolomide Combination Treatment in Patients With Newly Diagnosed or Recurrent Glioblastoma
Frequently asked questions
Who is developing mn-166?
mn-166 is being developed by MEDICINOVA INC.
How many clinical trials involve mn-166?
BioSniper tracks 1 clinical trial involving mn-166.
Get deeper analysis on mn-166
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis